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Abstract. The risk of colorectal cancer (CRC) is influence by polymorphisms located in the genes encoding enzymes of the
folate pathway. The aim of this study was to evaluate if 2R/3R TS (rs34743033) polymorphism is involved in predisposition for
colorectal in Romanian subjects. In the present case-control study, 75 sporadic CRC subjects and 60 healthy controls were
genotyped by PCR method. The frequency of 3R/3R genotype was 40% in control group and 42.7% in cancer group. We found that
there was no statistically significant association between the risk for CRC and 2R/3R TS polymorphism in Romanian subjects.
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INTRODUCTION
Folate deficiency may increase the risk of
colorectal cancer (CRC) through impaired DNA repair
synthesis and disruption of DNA methylation [3].
Epidemiological studies have suggested importance of
folate for CRC risk, particularly among individuals
who consume alcohol [17]. The risk may be modified
by polymorphisms in folate metabolizing genes [1, 10,
16].
Thymidylate synthase (TS) competes with MTHFR
for the 5-methyltetra-hydrofolate as the substrate for
i n t r a c e l l u l a r  c o n v e r s i o n  o f  d U M P  t o  d T M P  t h a t
represent a rate-limiting step in DNA synthesis [15].
A tandem repeat polymorphism was reported in the
promoter of TS gene containing either two (TS*2R) or
three (TS*3R) repeats of a 28-bp sequence. This
polymorphism has been shown to influence gene
expression [5]. Thus, individuals homozygous for triple
repeats (TS 3R/3R) have 3.6 times higher TS mRNA
levels compared with those homozygous for the double
repeat (TS 2R/2R) genotype [14].
Repeated sequences in 5’-terminal domain of the
TS are believed to regulate gene expression by forming
secondary structures [8]. Overexpression of the TS
protein was linked to resistance to 5-FU based
treatment and associated with poor survival outcomes
[13].
This polymorphism modified CRC risk and the
survival rate after the disease and the response to 5-FU-
based therapy [2, 8]. Also, the TS promoter
polymorphism may be a risk factor of the colorectal
adenomas [7, 18].
The goal of this study was to assess the possible
association between 28 bp variable number of tandem
repeat TS polymorphism (rs34743033) and
susceptibility to CRC in Romanian subjects.
MATERIALS AND METHODS
Study subjects
Between January 2008 and June 2009, blood
samples were obtained from 135 individuals. They
have been considered as two groups: 75 sporadic CRC
subjects and 60 controls.  Medical information’s
regarding cancer type, tumour location and clinical
evolution for subjects diagnosed with CRC were
obtained. The healthy controls, without known family
history of malignancies and cardio-vascular diseases
were selected from persons who attended N. Paulescu
Institute (Bucharest) for routine analysis. The Research
Ethics Committee of N. Paulescu Institute approved
this study and the research is in concordance with
principles of the Declaration of Helsinki. After
informed consent was obtained from each participant,
three ml of blood were collected in a tube containing
EDTA.
Genotyping
DNA was extracted from peripheral blood
leukocytes using Genomic Wizard DNA Purification
Kit ( P r o m e g a ,  M a d i s o n ,  W i s c o n s i n ,  U S A )  a n d  t h e
polymorphisms were detected by PCR as described
elsewhere [6]. Briefly, about 60 ng DNA were
amplified in a final volume of 10 μL, containing
1×PCR buffer, 1.5mmol/L MgCl2, 1 unit Taq DNA
polymerase (Promega, Madison, Wisconsin, USA), 100
μmol/L dNTP, and 0.5 μmol/L of each primer (sense
5’-CGT GGC TCC TGC GTT TCC-3’ and antisense
5’-GAG CCG GCC ACA GGC AT-3’). PCR was
performed in a Corbett research thermocycler (Corbett
Research Pty Ltd, Sydney, Australia) and the program
consisted in an initial melting step of 1 min at 94°C,
followed by 35 cycles of 1 min at 94°C, 1 min at 64°C,
and 1 min at 72°C, and a final elongation step of 1 min
at 72°C. Products of 210 bp (2R/2R), 238 bp (3R/3R)
or both of these products (2R/3R) were electrophoresed
(agarose 2%) and were visualized using Bio-Imaging
System (UVP Inc, Upland, Canada) after ethidium
bromide staining.
Statistical analysis
The distribution of genotypes in cancer and control
lots was first tested for the Hardy-Weinberg
equilibrium condition. The Chi-square test (χ
2, with a
value of p<0.05 considered statistically significant) was
used to compare the distribution of genotypes and
alleles in subjests and control groups. Odds ratios
(ORs) and 95% confidence intervals (CIs) were
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programs [20]. Also, Cochrane-Armitage test for trend
was performed using the DeFinetti program [21].
RESULTS
The 28 bp variable number of tandem repeat TS
polymorphism was genotyped in 75 subjects with CRC
and 60 healthy controls. The male proportion was 56%
in cases and 45% in controls. Mean age was for cases
63.7±4.8 and in controls 62.3±3.8. The colorectal
tumours were localized in colon and sigmoid (54.7% of
cases) and in rectum (45.3% of cases).
The frequencies of genotypes and alleles of
analyzed polymorphism are shown in Table 1. The
genotypes were distributed in accordance to Hardy-
Weinberg equilibrium expectation for both groups. No
statistically significant differences in the distribution of
polymorphism between cancer and control lots have
been identified.
Table 1. The distribution of TS genotypes and alleles between cancer and control groups
Genotype / alleles Cancer
N (%)
Control
N(%) OR (95%CI)
 a χ
2(p)
 b
3R/3R
32
(42.7)
24
(40)
1.11
(0.55-2.22)
0.098
(0.75)
2R/3R
29
(38.7)
22
(36.7)
1.08
(0.54-2.19)
0.057
(0.81)
2R/2R
14
(18.6)
14
(23.3)
0.75
(0.32-1.73)
0.442
(0.50)
3R
93
(62)
70
(58.3)
1.16
(0.71-1.90)
0.375
(0.54)
2R
57
(38)
50
(41.7)
0.85
(0.52-1.40)
0.375
(0.54)
Note:
a odds ratio and 95% confidence interval;
bValues of Chi squares and p.
The distribution of analyzed polymorphism
genotypes in relation with some characteristics of
subjects is show in Table 2. No statistically significant
differences in the frequencies of genotype have been
identified in relation with gender, age of onset or
localization of tumours (Table 2).
Table 2. The distribution of TS polymorphism in relation with some characteristics of CRC subjects
               Gender of subjects
2R/3R TS poymorphism
Male
N (%)
Female
N (%) OR (95%CI)
a χ
2(p)
b
3R/3R
18
(42.9)
14
(42.4)
1.01
(0.40-2.55)
0.001 (0.96)
2R/3R
15
(35.7)
14
(42.4)
0.75
(0.29-1.92)
0.351 (0.55)
2R/2R
9
(21.4)
5
(15.2)
1.52
(0.45-5.09)
0.48 (0.48)
                   Age at diagnosis
2R/3R TS poymorphism
Age < 65 years
N (%)
Age ≥ 65years
N (%)
OR (95%CI)
a χ
2(p)
b
3R/3R
13
(38.2)
19
(46.3)
1.51
(0.53-4.27)
0.613 (0.43)
2R/3R
16
(47.1)
13
(31.7)
1.91
(0.74-4.90)
1.84 (0.17)
2R/2R
5
(14.7)
9
(22)
0.61
(0.18-2.04)
0.64 (0.42)
         Localization of tumors
2R/3R TS poymorphism
Colon + sigmoid
N (%)
Rectum
N (%)
OR (95%CI)
a χ
2(p)
b
3R/3R
17
(41.5)
15
(44.1)
0.42
(0.15-1.19)
2.68
(0.10)
2R/3R
18
(43.9)
11
(32.4)
1.63
(0.63-4.21)
1.045
(0.30)
2R/2R
6
(14.6)
8
(23.5)
0.55
(0.17-1.80)
0.969
(0.32)
Note:
a odds ratio and 95% confidence interval;
bValues of Chi squares and p.
When we applied the Cochrane-Armitage test, there
was no significant association trend between alleles
and CRC (corrected OR2R= 0.87 and OR3R= 1.14; p=
0.57) or characteristics of subjects (gender, age at
diagnosis, and localization of tumors).
DISCUSSIONS
According to our knowledge, this is the first
research which investigates the association between
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subjects. The results show no statistically significant
association between the risk for CRC and some
characteristics of individuals and analyzed
polymorphism.
For controls group, the frequency of 3R/3R
genotype was 40% and of 3R allele 58.3%. This
represents the first report regarding this polymorphism
in Romanian population. We notice that the frequency
of 3R/3R genotype for our population is the highest
compared with those reported for other Caucasian
populations (about 29-38%) [2, 8, 11, 12]. This
variation of TS genotype between populations may
ne e d  to  b e  tak e n i nto  ac c o u nt f o r in iti at io n o f  5 - FU
therapy for Romanian CRC subjects.
Although other studies indicate that 2R/3R TS
polymorphism is associated with the risk of CRC [5,
1 1 ] ,  w e  f o u n d  a n y  r e l a t i o n  f o r  o u r  l o t s .  C h e n  a n d
collaborators reported that compared to TS 3R/3R
genotype, the multivariate-adjusted risk ratio was 0.86
(0.59 –1.25) for the 2R/3R genotype and 0.59 (0.36–
0.98) for the 2R/2R genotype (P for trend 0.03) [2].
In our study, we don’t find any relation between
gender of subjects and the distribution of genotype or
allele. This result is in contradiction with a previous
report that shows gender difference in the benefit from
5-FU-based adjuvant chemotherapy among colorectal
cancer individuals [4].
Recently, has been studied in relation with CRC
other polymorphisms in the TS gene. A 6-bp deletion
in the 3’untranslated region of the TS gene (TS
1494del6) has been identified [19], del6 allele being
associated with low TS mRNA stability and low TS
expression in comparison with ins6 allele [11]. In the
second repeat of 3R alleles a G > C polymorphism has
been shown to alter the transcriptional activation of the
gene [21]. The 3G allele has been associated with
higher reporter gene activity at both DNA
transcriptional and mRNA translational levels than the
3C allele, and 3G-containing genotypes (2R/3G,
3C/3G, 3G/3G) showed correlation with high TS
mRNA expression [9].
We found that there was no statistically significant
as s o c iatio n b e tw e e n t he  r is k  f o r C R C  and 2R/3R TS
polymorphism in Romanian subjects.
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